Expectant management of severe preeclampsia remote from term: A structured systematic review

Hypertension in Pregnancy

Volumn 28, Issue 3, 2009, Pages 312-347

  Magee, L A ^a   Yong, P J ^a   Espinosa, V ^a   Cote A M ^a   Chen, I ^a   Von Dadelszen, P ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Maternal morbidity and mortality; Perinatal morbidity and mortality; Preeclampsia

Indexed keywords

ANTIHYPERTENSIVE AGENT; CORTICOSTEROID; MAGNESIUM SULFATE;

ADVERSE OUTCOME; ARTICLE; CLINICAL TRIAL; DELIVERY; DISEASE SEVERITY; HELLP SYNDROME; HUMAN; MATERNAL HYPERTENSION; MATERNAL MORBIDITY; NEWBORN DEATH; OBSERVATIONAL STUDY; PERINATAL MORTALITY; PREECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATION; RANDOMIZED CONTROLLED TRIAL; STILLBIRTH; SYSTEMATIC REVIEW; TERTIARY HEALTH CARE; TREATMENT OUTCOME;

FEMALE; GESTATIONAL AGE; HELLP SYNDROME; HUMANS; MULTIVARIATE ANALYSIS; PRE-ECLAMPSIA; PREGNANCY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 65649142375     PISSN: 10641955     EISSN: 15256065     Source Type: Journal    
DOI: 10.1080/10641950802601252     Document Type: Article

References (81)

1. Schiff E, Friedman SA, Sibai BM. Conservative management of severe preeclampsia remote from term. Obstet Gynecol 1994; 84:626-630
2. Odendaal HJ, Pattinson RC, Bam R, Grove D, Kotze TJ. Aggressive or expectant management for patients with severe preeclampsia between 28-34 weeks' gestation: a randomized controlled trial. Obstet Gynecol 1990; 76:1070-1075.
3. Sibai BM, Mercer BM, Schiff E, Friedman SA. Aggressive versus expectant management of severe preeclampsia at 28 to 32 weeks' gestation: a randomized controlled trial. Am J Obstet Gynecol 1994; 171:818-822.
4. Churchill D, Duley L. Interventionist versus expectant care for severe preeclampsia before term. Cochrane Database Syst Rev 2002; CD003106.
5. Magee LA, Ornstein MP, von Dadelszen P. Fortnightly review: management of hypertension in pregnancy. BMJ 1999; 318:1332-1336.
6. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M et al. The Newcastle- Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in metaanalyses. www.ohri.ca/programs/clinical-epidemiology/oxford.htm 2008.
7. Bolte AC, van Eyck J, Gaffar SF, van Geijn HP, Dekker GA. Ketanserin for the treatment of preeclampsia. J Perinat Med 2001; 29:14-22.
8. Budden A, Wilkinson L, Buksh MJ, McCowan L. Pregnancy outcome in women presenting with preeclampsia at less than 25 weeks gestation. Aust NZ J Obstet Gynaecol 2006; 46:407-412.
9. De Boer K, Buller HR, Ten Cate JW, Treffers PE. Coagulation studies in the syndrome of haemolysis, elevated liver enzymes and low platelets. Br J Obstet Gynaecol 1991; 98:42-47.
10. Derham RJ, Hawkins DF, De Vries LS, Aber VR, Elder MG. Outcome of pregnancies complicated by severe hypertension and delivered before 34 weeks; stepwise logistic regression analysis of prognostic factors. Br J Obstet Gynaecol 1989; 96:1173-1181.
11. Dreyfus M, Tissier I, Ndocko MA, Denoual I, Baldauf JJ, Ritter J. Corticosteroid therapy for conservative management in marginally-viable pregnancy complicated by HELLP syndrome. Eur J Obstet Gynecol Reprod Biol 1999; 85:233-234.
12. Fenakel K, Fenakel G, Appelman Z, Lurie S, Katz Z, Shoham Z. Nifedipine in the treatment of severe preeclampsia. Obstet Gynecol 1991; 77:331-337.
13. Friedman SA, Schiff E, Kao L, Sibai BM. Neonatal outcome after preterm delivery for preeclampsia. Am J Obstet Gynecol 1995; 172:1785-1788.
14. Haddad B, Barton JR, Livingston JC, Chahine R, Sibai BM. HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome versus severe preeclampsia: onset at < or = 28.0 weeks' gestation. Am J Obstet Gynecol 2000; 183:1475-1479 (Pubitemid 32061210)
15. Harms K, Rath W, Herting E, Kuhn W. Maternal hemolysis, elevated liver enzymes, low platelet count, and neonatal outcome. Am J Perinatol 1995; 12:1-6.
16. Hjertberg R, Belfrage P, Hagnevik K. Hemodynamic measurements with Swan-Ganz catheter in women with severe proteinuric gestational hypertension (preeclampsia). Acta Obstet Gynecol Scand 1991; 70:193-198.
17. Isler CM, Barrilleaux PS, Magann EF, Bass JD, Martin JN, Jr. A prospective, randomized trial comparing the efficacy of dexamethasone and betamethasone for the treatment of antepartum HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome. Am J Obstet Gynecol 2001; 184:1332-1337.
18. Izquierdo LA, Gilson GJ, Urquhart ST, Gardner MO, Rappaport VM, Curet LB. Analysis of expectant versus active management of in patients with severe preeclampsia between 24 and 34 weeks of gestational age. Prenat Neonat Med 1998; 3:323-326.
19. Jenkins SM, Head BB, Hauth JC. Severe preeclampsia at <25 weeks of gestation: Maternal and neonatal outcomes. Am J Obstet Gynecol 2002; 186:790-795
20. Kirsten GF, Van Zyl JI, Van Zijl F, Maritz JS, Odendaal HJ. Infants of women with severe early preeclampsia: the effect of absent end-diastolic umbilical artery doppler flow velocities on neurodevelopmental outcome. Acta Paediatr 2000; 89:566-570.
21. Kobayashi T, Terao T, Ikenoue T, Sameshima H, Nakabayashi M, Kajiwara Y, et al. Treatment of severe preeclampsia with antithrombin concentrate: results of a prospective feasibility study. Semin Thromb Hemost 2003; 29:645-652.
22. Magann EF, Martin RW, Isaacs JD, Blake PG, Morrison JC, Martin JN, Jr. Corticosteroids for the enhancement of fetal lung maturity: impact on the gravida with preeclampsia and the HELLP syndrome. Aust NZ J Obstet Gynaecol 1993; 33:127-131.
23. Magann EF, Bass D, Chauhan SP, Sullivan DL, Martin RW, Martin JN, Jr. Antepartum corticosteroids: disease stabilization in patients with the syndrome of hemolysis, elevated liver enzymes, and low platelets (HELLP). Am J Obstet Gynecol 1994; 171:1148-1153.
24. O'Brien JM, Milligan DA, Barton JR. Impact of high-dose corticosteroid therapy for patients with HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome. Am J Obstet Gynecol 2000; 183:921-924.
25. O'Brien JM, Shumate SA, Satchwell SL, Milligan DA, Barton JR. Maternal benefit of corticosteroid therapy in patients with HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome: impact on the rate of regional anesthesia. Am J Obstet Gynecol 2002; 186:475-479.
26. Odendaal HJ, Hall DR, Grove D. Risk factors for and perinatal mortality of abruptio placentae in patients hospitalised for early onset severe preeclampsia - a case controlled study. J Obstet Gynaecol 2000; 20:358-364.
27. Roes EM, Raijmakers MT, Boo TM, Zusterzeel PL, Merkus HM, Peters WH, et al. Oral N-acetylcysteine administration does not stabilise the process of established severe preeclampsia. Eur J Obstet Gynecol Reprod Biol 2006; 127:61-67.
28. Ruvinsky ED, Douvas SG, Roberts WE, Martin JN, Jr., Palmer SM, Rhodes PG, et al. Maternal administration of dexamethasone in severe pregnancy-induced hypertension. Am J Obstet Gynecol 1984; 149:722-726.
29. Sibai BM, Gonzalez AR, Mabie WC, Moretti M. A comparison of labetalol plus hospitalization versus hospitalization alone in the management of preeclampsia remote from term. Obstet Gynecol 1987; 70:323-327.
30. Tompkins MJ, Thiagarajah S. HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome: the benefit of corticosteroids. Am J Obstet Gynecol 1999; 181:304-309.
31. van Pampus MG, Wolf H, Ilsen A, Treffers PE. Maternal outcome following temporizing management of the (H)ELLP syndrome. Hypertens Pregnancy 2000; 19:211-220.
32. Wide-Swensson D, Montan S, Arulkumaran S, Ingemarsson I, Ratnam SS. Effect of methyldopa and isradipine on fetal heart rate pattern assessed by computerized cardiotocography in human pregnancy. Am J Obstet Gynecol 1993; 169:1581-1585.
33. Rose CH, Thigpen BD, Bofill JA, Cushman J, May WL, Martin JN, Jr. Obstetric implications of antepartum corticosteroid therapy for HELLP syndrome. Obstet Gynecol 2004; 104:1011-1014.
34. Runnard Heimel PJ, Huisjes AJ, Franx A, Koopman C, Bots ML, Bruinse HW. A randomised placebo-controlled trial of prolonged prednisolone administration to patients with HELLP syndrome remote from term. Eur J Obstet Gynecol Reprod Biol 2006; 128:187-193.
35. Banias BB, Devoe LD, Nolan TE. Severe preeclampsia in preterm pregnancy between 26 and 32 weeks' gestation. Am J Perinatol 1992; 9:357-360.
36. Begum MR, Akhter S, Begum A, Khatun M, Quadir E, Choudhury SB. Conservative management of eclampsia and severe preeclampsia-A Bangladesh experience. Medscape Womens Health 2002; 7:1.
37. Blackwell SC, Redman ME, Tomlinson M, Berry SM, Sorokin Y, Cotton DB. Severe preeclampsia remote from term: what to expect of expectant management. J Matern Fetal Neonatal Med 2002; 11:321-324.
38. Chammas MF, Nguyen TM, Li MA, Nuwayhid BS, Castro LC. Expectant management of severe preterm preeclampsia: is intrauterine growth restriction an indication for immediate delivery? Am J Obstet Gynecol 2000; 183:853-858.
39. Chari RS, Friedman SA, O'Brien JM, Sibai BM. Daily antenatal testing in women with severe preeclampsia. Am J Obstet Gynecol 1995; 173:1207-1210.
40. Schiff E, Friedman SA, Kao L, Sibai BM. The importance of urinary protein excretion during conservative management of severe preeclampsia. Am J Obstet Gynecol 1996; 175:1313-1316.
41. Schucker JL, Mercer BM, Audibert F, Lewis RL, Friedman SA, Sibai BM. Serial amniotic fluid index in severe preeclampsia: a poor predictor of adverse outcome. Am J Obstet Gynecol 1996; 175:1018-1023.
42. Ganzevoort W, Rep A, Bonsel GJ, Fetter WP, van Sonderen L, De Vries JI et al. A randomised controlled trial comparing two temporising management strategies, one with and one without plasma volume expansion, for severe and early onset preeclampsia. BJOG 2005; 112:1358-1368.
43. Ganzevoort W, Rep A, Bonsel GJ, De Vries JI, Wolf H. A randomized trial of plasma volume expansion in hypertensive disorders of pregnancy: influence on the pulsatility indices of the fetal umbilical artery and middle cerebral artery. Am J Obstet Gynecol 2005; 192:233-239.
44. Haddad B, Deis S, Goffinet F, Paniel BJ, Cabrol D, Siba BM. Maternal and perinatal outcomes during expectant management of 239 severe preeclamptic women between 24 and 33 weeks' gestation. Am J Obstet Gynecol 2004; 190:1590-1595.
45. Hall DR, Odendaal HJ, Kirsten GF, Smith J, Grove D. Expectant management of early onset, severe preeclampsia: perinatal outcome. BJOG 2000; 107:1258-1264. (Pubitemid 30736195)
46. Hall DR, Odendaal HJ, Steyn DW, Grove D. Expectant management of early onset, severe preeclampsia: maternal outcome. BJOG 2000; 107:1252-1257. (Pubitemid 30736194)
47. Hall DR, Odendaal HJ, Steyn DW. Delivery of patients with early onset, severe preeclampsia. Int J Gynaecol Obstet 2001; 74:143-150.
48. Hall DR, Odendaal HJ, Steyn DW. Expectant management of severe preeclampsia in the mid-trimester. Eur J Obstet Gynecol Reprod Biol 2001; 96:168-172.
49. Hall DR, Odendaal HJ, Steyn DW, Grove D. Urinary protein excretion and expectant management of early onset, severe preeclampsia. Int J Gynaecol Obstet 2002; 77:1-6.
50. Hall DR, Grove D, Carstens E. Early preeclampsia: what proportion of women qualify for expectant management and if not, why not? Eur J Obstet Gynecol Reprod Biol 2006; 128:169-174.
51. Hanff LM, Vulto AG, Bartels PA, Roofthooft DW, Bijvank BN, Steegers EA et al. Intravenous use of the calcium-channel blocker nicardipine as secondline treatment in severe, early-onset preeclamptic patients. J Hypertens 2005; 23:2319-2326.
52. Moodley J, Koranteng SA, Rout C. Expectant management of early onset of severe preeclampsia in Durban. S Afr Med J 1993; 83:584-587.
53. Murphy DJ, Stirrat GM. Mortality and morbidity associated with early-onset preeclampsia. Hypertens Pregnancy 2000; 19:221-231.
54. Newman MG, Robichaux AG, Stedman CM, Jaekle RK, Fontenot MT, Dotson T et al. Perinatal outcomes in preeclampsia that is complicated by massive proteinuria. Am J Obstet Gynecol 2003; 188:264-268.
55. Odendaal HJ, Pattinson RC, du TR. Fetal and neonatal outcome in patients with severe preeclampsia before 34 weeks. S Afr Med J 1987; 71:555-558.
56. Odendaal HJ, Pattinson RC, du TR, Grove D. Frequent fetal heart-rate monitoring for early detection of abruptio placentae in severe proteinuric hypertension. S Afr Med J 1988; 74:19-21.
57. Odendaal HJ, Steyn DW, Norman K, Kirsten GF, Smith J, Theron GB. Improved perinatal mortality rates in 1001 patients with severe preeclampsia. S Afr Med J 1995; 85:1071-1076.
58. Odendaal HJ, Pienaar ME. Are high uric acid levels in patients with early preeclampsia an indication for delivery? S Afr Med J 1997; 87:213-218.
59. Pattinson RC, Odendaal HJ, du TR. Conservative management of severe proteinuric hypertension before 28 weeks' gestation. S Afr Med J 1988; 73:516-518.
60. Oettle C, Hall D, Roux A, Grove D. Early onset severe preeclampsia: expectant management at a secondary hospital in close association with a tertiary institution. BJOG 2005; 112:84-88.
61. Olah KS, Redman CW, Gee H. Management of severe, early preeclampsia: is conservative management justified? Eur J Obstet Gynecol Reprod Biol 1993; 51:175-180.
62. Onah HE, Iloabachie GC. Conservative management of early-onset preeclampsia and fetomaternal outcome in Nigerians. J Obstet Gynaecol 2002; 22:357-362.
63. Railton A, Allen DG. Management and outcome of pregnancy complicated by severe preeclampsia of early onset. S Afr Med J 1987; 72:608-610.
64. Shear RM, Rinfret D, Leduc L. Should we offer expectant management in cases of severe preterm preeclampsia with fetal growth restriction? Am J Obstet Gynecol 2005; 192:1119-1125.
65. Spinillo A, Iasci A, Capuzzo E, Egbe TO, Colonna L, Fazzi E. Two-year infant neurodevelopmental outcome after expectant management and indicated preterm delivery in hypertensive pregnancies. Acta Obstet Gynecol Scand 1994; 73:625-629.
66. Vigil-De Gracia P, Montufar-Rueda C, Ruiz J. Expectant management of severe preeclampsia and preeclampsia superimposed on chronic hypertension between 24 and 34 weeks' gestation. Eur J Obstet Gynecol Reprod Biol 2003; 107:24-27.
67. Visser W, van Pampus MG, Treffers PE, Wallenburg HC. Perinatal results of hemodynamic and conservative temporizing treatment in severe preeclampsia. Eur J Obstet Gynecol Reprod Biol 1994; 53:175-181.
68. Visser W, Wallenburg HC. Maternal and perinatal outcome of temporizing management in 254 consecutive patients with severe preeclampsia remote from term. Eur J Obstet Gynecol Reprod Biol 1995; 63:147-154.
69. Withagen MI, Visser W, Wallenburg HC. Neonatal outcome of temporizing treatment in early-onset preeclampsia. Eur J Obstet Gynecol Reprod Biol 2001; 94:211-215.
70. Withagen MI, Wallenburg HC, Steegers EA, Hop WC, Visser W. Morbidity and development in childhood of infants born after temporising treatment of early onset preeclampsia. BJOG 2005; 112:910-914. (Pubitemid 40896956)
71. Ganzevoort W, Rep A, Bonsel GJ, De Vries JI, Wolf H. Dynamics and incidence patterns of maternal complications in early-onset hypertension of pregnancy. BJOG 2007; 114:741-750.
72. Visser W, Wallenburg HC. Temporising management of severe preeclampsia with and without the HELLP syndrome. Br. J Obstet Gynaecol. 1995; 102:111-117.
73. Gaugler-Senden IP, Huijssoon AG, Visser W, Steegers EA, de Groot CJ. Maternal and perinatal outcome of preeclampsia with an onset before 24 weeks' gestation. Audit in a tertiary referral center. Eur J Obstet Gynecol Reprod Biol 2006; 128:216-221.
74. Sibai BM, Akl S, Fairlie F, Moretti M. A protocol for managing severe preeclampsia in the second trimester. Am J Obstet Gynecol 1990; 163:733-738.
75. Chua S,.Redman CW. Prognosis for preeclampsia complicated by 5 g or more of proteinuria in 24 hours. Eur J Obstet Gynecol Reprod Biol 1992; 43:9-12.
76. Haddad B, Kayem G, Deis S, Sibai BM. Are perinatal and maternal outcomes different during expectant management of severe preeclampsia in the presence of intrauterine growth restriction? Am J Obstet Gynecol 2007; 196:237-1235
77. Haddad B, Cabrol D, Cynober E, Paniel BJ. Severe uterine diastolic notch as a prognostic factor in preeclamptic women. Eur J Obstet Gynecol Reprod Biol 1999; 85:179-183.
78. Ganzevoort W, Rep A, De Vries JI, Bonsel GJ, Wolf H. Prediction of maternal complications and adverse infant outcome at admission for temporizing management of early-onset severe hypertensive disorders of pregnancy. Am J Obstet Gynecol 2006; 195:495-503.
79. Odendaal HJ, Pattinson RC, Bam R, Grove D, Kotze TJ. Aggressive or expectant management for patients with severe preeclampsia between 28-34 weeks' gestation: a randomized controlled trial. Obstet Gynecol 1990; 76:1070-1075.
80. Sibai BM, Mercer BM, Schiff E, Friedman SA. Aggressive versus expectant management of severe preeclampsia at 28 to 32 weeks' gestation: a randomized controlled trial. Am J Obstet Gynecol 1994; 171:818-822.
81. Menzies J, Magee LA, Li J, Macnab YC, Yin R, Stuart H et al. Instituting surveillance guidelines and adverse outcomes in preeclampsia. Obstet Gynecol 2007; 110:121-127.